Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Drug manufacturers soon developed offerings of the drug that are expressly approved for use in weight loss. It may seem like everyone is taking a GLP-1 agonist these days, but individuals who are ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

The FDA has approved Hikma Pharmaceuticals’ generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve ...

Key Trends: New Drug Approvals: - 3 new GLP-1 agonists received FDA approval in 2021 alone, expanding treatment options for patients. Increasing Obesity Rates: - Over 42% of Americans now face ...

The region’s largest health insurer said it will only cover the drug for its FDA-approved uses ... Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The U.S. Food and Drug Administration (FDA) has approved the first prescription ... the FDA stated that Zepbound, part of the GLP-1 receptor agonist medicines that include Ozempic, was cleared ...

the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ...